Surveillance of HFMD in Pediatric Outpatients
Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Feb 15, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Surveillance of HFMD in Pediatric Outpatients," is focused on understanding the different types of viruses that cause Hand, Foot, and Mouth Disease (HFMD) and herpangina in children. Researchers want to find out if there are any new or unusual strains of these viruses and how they affect children differently. By studying this, they hope to catch any outbreaks early and learn more about how these infections behave.
The study is currently looking for children aged 0 to 10 years who have been diagnosed with HFMD or herpangina. Parents or guardians will need to agree to let their child participate, and children older than 3 years must also consent. If your child joins the trial, they will undergo some tests to help researchers gather important information about these diseases. Participation can contribute to better understanding and treatment of these common childhood illnesses.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children aged 0 to 10 years presenting with HFMD or herpangina
- Exclusion Criteria:
- • Refusal to participate by holders of parental authority
- • Refusal to participate for children over 3 years of age
About University Hospital, Clermont Ferrand
The University Hospital of Clermont-Ferrand is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its multidisciplinary approach, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes collaboration among healthcare professionals, researchers, and academic partners. With a strong commitment to improving patient outcomes, the institution actively engages in a wide array of clinical studies, ranging from early-phase trials to large-scale interventions, aimed at addressing critical health challenges and enhancing treatment modalities. Its state-of-the-art facilities and expertise make it a pivotal contributor to clinical research in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clermont Ferrand, , France
Patients applied
Trial Officials
Audrey MIRAND
Principal Investigator
University Hospital, Clermont-Ferrand
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported